In patients with atherosclerotic cardiovascular disease (ASCVD), initiating statin–ezetimibe combination therapy within a target-directed low-density lipoprotein cholesterol (LDL-C)–lowering strategy increases success in hitting lower LDL-C targets but does not appear to provide extra protection against adverse cardiovascular (CV) events compared with statin monotherapy, according to the Ez-PAVE trial.
In the second randomization of the Ez-PAVE trial, patients who received statin–ezetimibe combination therapy achieved lower median LDL-C levels during the 3-year follow-up compared with those who received statin monotherapy in both the intensive (<55 mg/dL) LDL-C-targeting strategy (53 vs 62 mg/dL) and conventional (<70 mg/dL) LDL-C-targeting strategy (63 vs 70 mg/dL), reported Dr Byeong-Keuk Kim from Yonsei University College of Medicine, Seoul, South Korea. [Circulation 2026;doi:10.1161/CIRCULATIONAHA.126.08381]
However, the incidence of the composite of CV death, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina at 3 years did not significantly differ between the statin–ezetimibe and statin monotherapy groups (8.5 percent vs 7.9 percent, respectively; hazard ratio [HR], 1.07, 95 percent confidence interval [CI], 0.83–1.37; p=0.596).
Kim noted no significant between-group differences were observed in safety outcomes, including new-onset diabetes, worsening of glycaemic control, statin-associated muscle symptoms, cancer diagnosis, cataract surgery, and laboratory findings (ie, elevation in aminotransferase, creatinine, or creatinine kinase).
In light of the findings, Kim emphasized that achieving the assigned LDL-C target through timely treatment adjustment may ultimately be more important for clinical outcomes than the choice of initial regimen.
Not enough power
The Ez-PAVE trial had a two-by-two factorial design. The results of the first randomization, which were reported early this year, showed that lowering LDC-C levels to target of <55 mg/dL significantly reduced the incidence of adverse CV events compared with a target of <70 mg/dL (6.6 percent vs 9.7 percent; HR, 0.67, 95 percent CI, 0.52–0.86; p=0.002). [N Engl J Med 2026;394:1365-1375]
“We can see that the original analysis from Ez-PAVE established that an LDL-C <55 mg/dL is superior to an LDL-C <70 mg/dL in reducing major adverse CV events. But in this second randomization, it simply didn’t have the power to determine whether the starting approach really changes clinical outcomes,” noted study discussant Dr Michael Shapiro from Wake Forest University School of Medicine, North Carolina, US.
Shapiro pointed out that based on Cholesterol Treatment Trialists’ (CTT) Collaboration benchmarks—where every 40 mg/dL reduction in LDL-C yields a 22-percent reduction in major adverse CV events—the modest LDL-C difference observed between the statin–ezetimibe and the statin monotherapy groups would translate to only a 4-percent to 5-percent relative risk reduction.
“That would require thousands of events, much more than the 247 events that were observed in this trial to be able to detect a difference,” he said.
Because the second randomization did not have the power to detect differences, “the absence of a difference does not establish equivalence between the two starting [LDL-C-lowering treatment] approaches,” he continued.
Shapiro also emphasized that in the trial, one in three patients in the statin monotherapy group who were assigned a target of <55 mg/dL received ezetimibe during years 2–3 and 74 percent of patients received high-intensity statin by month 1, making the trial a comparison of upfront combination therapy vs protocol-driven stepped care rather than statin monotherapy.
Taken together, Ez-PAVE “shows us that outside of protocolized care, upfront combination may provide a more reliable path to early LDL-C control,” he concluded.
Ez-PAVE
Conducted across multiple centres in South Korea, Ez-PAVE included 3,048 patients with ASCVD (mean age 64.4 years, 20.9 percent female). Following the first randomization to either an intensive or conventional LDL-C–targeting strategy, patients underwent subsequent randomization to receive initial statin–ezetimibe combination therapy (n=1,525) or statin monotherapy (n=1,523). Patients were followed up for 3 years.
Lipid-lowering therapy was adjusted according to a predefined protocol to achieve LDL-C targets. During the follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3 percent) and 177 patients (24.8 percent) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively.
“The treatment effect of intensive-targeting vs conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity (p=0.583 for interaction),” Kim noted.